KR100455797B1 - 미립상 형태의 테트라히드로피리딘 유도체 - Google Patents

미립상 형태의 테트라히드로피리딘 유도체 Download PDF

Info

Publication number
KR100455797B1
KR100455797B1 KR10-1999-7005372A KR19997005372A KR100455797B1 KR 100455797 B1 KR100455797 B1 KR 100455797B1 KR 19997005372 A KR19997005372 A KR 19997005372A KR 100455797 B1 KR100455797 B1 KR 100455797B1
Authority
KR
South Korea
Prior art keywords
particles
less
active ingredient
microparticles
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1999-7005372A
Other languages
English (en)
Korean (ko)
Other versions
KR20000069503A (ko
Inventor
까롱앙뚜완
샹봉쟝-삐에르
모니에올리비에
Original Assignee
사노피-신델라보
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-신델라보 filed Critical 사노피-신델라보
Publication of KR20000069503A publication Critical patent/KR20000069503A/ko
Application granted granted Critical
Publication of KR100455797B1 publication Critical patent/KR100455797B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
KR10-1999-7005372A 1996-12-23 1997-12-23 미립상 형태의 테트라히드로피리딘 유도체 Expired - Fee Related KR100455797B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR96/15905 1996-12-23
FR9615905A FR2757510B1 (fr) 1996-12-23 1996-12-23 Forme microparticulaire d'un derive de tetrahydropyridine
PCT/FR1997/002394 WO1998028272A1 (fr) 1996-12-23 1997-12-23 Forme microparticulaire d'un derive de tetrahydropyridine

Publications (2)

Publication Number Publication Date
KR20000069503A KR20000069503A (ko) 2000-11-25
KR100455797B1 true KR100455797B1 (ko) 2004-11-06

Family

ID=9499044

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7005372A Expired - Fee Related KR100455797B1 (ko) 1996-12-23 1997-12-23 미립상 형태의 테트라히드로피리딘 유도체

Country Status (37)

Country Link
US (4) US20020028247A1 (cg-RX-API-DMAC10.html)
EP (1) EP0950051B1 (cg-RX-API-DMAC10.html)
JP (2) JP4422214B2 (cg-RX-API-DMAC10.html)
KR (1) KR100455797B1 (cg-RX-API-DMAC10.html)
CN (1) CN1088698C (cg-RX-API-DMAC10.html)
AR (1) AR009673A1 (cg-RX-API-DMAC10.html)
AT (1) ATE250032T1 (cg-RX-API-DMAC10.html)
AU (1) AU730302B2 (cg-RX-API-DMAC10.html)
BR (1) BR9714177A (cg-RX-API-DMAC10.html)
CA (1) CA2275593C (cg-RX-API-DMAC10.html)
CO (1) CO4920213A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ294272B6 (cg-RX-API-DMAC10.html)
DE (1) DE69724999T2 (cg-RX-API-DMAC10.html)
DK (1) DK0950051T3 (cg-RX-API-DMAC10.html)
DZ (1) DZ2386A1 (cg-RX-API-DMAC10.html)
EE (1) EE04112B1 (cg-RX-API-DMAC10.html)
EG (1) EG24749A (cg-RX-API-DMAC10.html)
ES (1) ES2207758T3 (cg-RX-API-DMAC10.html)
FR (1) FR2757510B1 (cg-RX-API-DMAC10.html)
HU (1) HU224348B1 (cg-RX-API-DMAC10.html)
IL (1) IL129937A (cg-RX-API-DMAC10.html)
IN (1) IN186977B (cg-RX-API-DMAC10.html)
IS (1) IS2064B (cg-RX-API-DMAC10.html)
MY (1) MY126298A (cg-RX-API-DMAC10.html)
NO (1) NO311569B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ336129A (cg-RX-API-DMAC10.html)
PL (1) PL190098B1 (cg-RX-API-DMAC10.html)
PT (1) PT950051E (cg-RX-API-DMAC10.html)
RU (1) RU2193031C2 (cg-RX-API-DMAC10.html)
SI (1) SI0950051T1 (cg-RX-API-DMAC10.html)
SK (1) SK283917B6 (cg-RX-API-DMAC10.html)
TR (1) TR199901362T2 (cg-RX-API-DMAC10.html)
TW (1) TW534820B (cg-RX-API-DMAC10.html)
UA (1) UA66776C2 (cg-RX-API-DMAC10.html)
WO (1) WO1998028272A1 (cg-RX-API-DMAC10.html)
YU (1) YU49427B (cg-RX-API-DMAC10.html)
ZA (1) ZA9711579B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2739852T3 (es) * 2001-07-06 2020-02-04 Veloxis Pharmaceuticals As Aglomeración controlada
BE1015641A4 (fr) * 2003-05-26 2005-07-05 Mariani Jean Paul Micronisation 70.
RU2472490C1 (ru) * 2011-08-05 2013-01-20 Открытое акционерное общество "Биосинтез" Средство для лечения кожных гнойных инфекций, составы и способы получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562883A (en) * 1896-06-30 Thill-coupling
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
ES2127835T3 (es) * 1992-10-26 1999-05-01 Sanol Arznei Schwarz Gmbh Procedimiento para la preparacion de microcapsulas.
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US6489334B2 (en) * 1996-12-23 2002-12-03 Sanofi-Synthelabo Method for the crystallization of a tetrahydropyridin derivative and resulting crystalline forms
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors

Also Published As

Publication number Publication date
DE69724999T2 (de) 2004-07-22
FR2757510B1 (fr) 2000-01-07
PT950051E (pt) 2004-02-27
US20100021541A1 (en) 2010-01-28
DE69724999D1 (de) 2003-10-23
TR199901362T2 (xx) 1999-09-21
EP0950051A1 (fr) 1999-10-20
CZ229199A3 (cs) 1999-09-15
IS5077A (is) 1999-06-10
NO993077L (no) 1999-06-22
CN1241179A (zh) 2000-01-12
IL129937A0 (en) 2000-02-29
HUP0001181A2 (hu) 2000-11-28
ATE250032T1 (de) 2003-10-15
ES2207758T3 (es) 2004-06-01
AU730302B2 (en) 2001-03-01
UA66776C2 (uk) 2004-06-15
PL334276A1 (en) 2000-02-14
EG24749A (en) 2010-07-20
NO311569B1 (no) 2001-12-10
TW534820B (en) 2003-06-01
SK283917B6 (sk) 2004-05-04
CZ294272B6 (cs) 2004-11-10
US20020028247A1 (en) 2002-03-07
SI0950051T1 (en) 2004-02-29
CN1088698C (zh) 2002-08-07
CA2275593C (en) 2005-12-20
AR009673A1 (es) 2000-04-26
IN186977B (cg-RX-API-DMAC10.html) 2001-12-22
EE04112B1 (et) 2003-08-15
US20020192292A1 (en) 2002-12-19
HUP0001181A3 (en) 2003-03-28
YU28899A (sh) 2000-03-21
BR9714177A (pt) 2000-02-29
RU2193031C2 (ru) 2002-11-20
NZ336129A (en) 2000-11-24
IS2064B (is) 2005-11-15
YU49427B (sh) 2006-01-16
KR20000069503A (ko) 2000-11-25
ZA9711579B (en) 1998-06-25
EE9900263A (et) 2000-02-15
AU5668598A (en) 1998-07-17
US20080255365A1 (en) 2008-10-16
HU224348B1 (hu) 2005-08-29
CO4920213A1 (es) 2000-05-29
JP2009280581A (ja) 2009-12-03
FR2757510A1 (fr) 1998-06-26
PL190098B1 (pl) 2005-10-31
NO993077D0 (no) 1999-06-22
IL129937A (en) 2002-09-12
DZ2386A1 (fr) 2002-12-28
HK1024000A1 (en) 2000-09-29
JP4422214B2 (ja) 2010-02-24
SK82999A3 (en) 1999-12-10
DK0950051T3 (da) 2004-01-26
WO1998028272A1 (fr) 1998-07-02
CA2275593A1 (en) 1998-07-02
MY126298A (en) 2006-09-29
EP0950051B1 (fr) 2003-09-17
JP2001507013A (ja) 2001-05-29

Similar Documents

Publication Publication Date Title
JP4334869B2 (ja) 溶解性または経口吸収性の改善された組成物
TWI389691B (zh) 可口服且具有活性成分快速釋出之固態醫藥劑型
US7108864B1 (en) Tablet formation
SK140694A3 (en) Preparations with permanent release of effective component and method of their preparation
EP1928427B1 (en) Novel dosage formulation
CN109793715B (zh) 一种阿哌沙班口服固体制剂及其制备方法
EA007185B1 (ru) Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
TWI380829B (zh) 具有改良的生物可利用率之普侖斯特（ｐｒａｎｌｕｋａｓｔ）固態分散物組成物及製備該固態分散物之方法
HK1205683A1 (en) Pharmaceutical formulation having improved stability
US20100021541A1 (en) Microparticulate form of a Tetrahydropyridine derivative
WO2009146608A1 (zh) 含有咪唑5-羧酸类衍生物的药用组合物，其制备方法及用途
KR102090135B1 (ko) 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 포함하는 구강 붕해정 및 이의 제조방법
HRP970701A2 (en) Micro-particulate form of a tetrahydropyridin derivative
JP4499188B2 (ja) テトラヒドロピリジン誘導体を結晶化する方法及び得られる結晶形
MXPA99005621A (en) Micro-particulate form of a tetrahydropyridin derivative
SA98180973B1 (ar) شكل جسيمي متناهي في الصغر من مشتق رباعي هيدرو بيريدين tetrahydropyridine
WO2010115342A1 (zh) 含有四氢吡啶[4，3-b]吲哚衍生物的缓释组合物及该衍生物的制备方法
CN102485225A (zh) 用于治疗细菌感染的药物组合物
JP2813792B2 (ja) マレイン酸イルソグラジン経口投与用製剤およびその製造法
HK1024000B (en) Micro-particulate form of a tetrahydropyridin derivative
CN102485224B (zh) 制备微粉化噁唑烷酮类药物的方法及微粉化的药物组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20110920

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20121028

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20121028

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000